Free Trial
NASDAQ:KZIA

Kazia Therapeutics (KZIA) Stock Price, News & Analysis

$0.28
+0.01 (+3.71%)
(As of 05/24/2024 ET)
Today's Range
$0.27
$0.29
50-Day Range
$0.22
$0.46
52-Week Range
$0.19
$1.34
Volume
27,477 shs
Average Volume
615,310 shs
Market Capitalization
$4.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Kazia Therapeutics MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.53% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.03mentions of Kazia Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.40) to ($0.33) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.27 out of 5 stars

KZIA stock logo

About Kazia Therapeutics Stock (NASDAQ:KZIA)

Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth factor receptor 3 inhibitor. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.

KZIA Stock Price History

KZIA Stock News Headlines

Kazia Therapeutics Ltd ADR KZIA
KZIA Apr 2024 2.500 call
Kazia Therapeutics Limited
Kazia Therapeutics Ltd. ADR
Viking Therapeutics, Inc. Common Stock (VKTX)
KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS
Kazia Therapeutics Announces Registered Direct Offering - Quick Facts
See More Headlines
Receive KZIA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kazia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
5/24/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KZIA
Employees
2,021
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$20,000.00
Book Value
$0.50 per share

Miscellaneous

Free Float
16,178,000
Market Cap
$4.56 million
Optionable
Optionable
Beta
2.07
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. John Edwin Friend II (Age 54)
    M.D., CEO, MD & Director
    Comp: $707.94k
  • Ms. Gabrielle Heaton BBUS (ACC)
    CPA, Principal Accounting Officer, VP of Finance & Administration and Principal Financial Officer
  • Ms. Anna Sandham
    Company Secretary

KZIA Stock Analysis - Frequently Asked Questions

How have KZIA shares performed in 2024?

Kazia Therapeutics' stock was trading at $0.4395 at the start of the year. Since then, KZIA stock has decreased by 36.5% and is now trading at $0.2793.
View the best growth stocks for 2024 here
.

What other stocks do shareholders of Kazia Therapeutics own?
How do I buy shares of Kazia Therapeutics?

Shares of KZIA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KZIA) was last updated on 5/24/2024 by MarketBeat.com Staff

From Our Partners